Abstract

Chordomas are rare, malignant bone tumors that arise from remnants of the notochord, primarily affecting the axial skeleton. Despite their slow growth, they present significant clinical challenges due to their proximity to critical structures, high recurrence rates, and resistance to conventional therapies. Recent advancements in molecular biology and tumor genetics have led to the development of novel therapeutic approaches aimed at targeting key biological pathways driving chordoma progression. This article explores the latest breakthroughs in chordoma research, including immunotherapies, targeted molecular agents, and precision medicine strategies. By unlocking the intricacies of tumor biology, these game-changing therapies offer new hope for improving patient outcomes and mitigating the burden of this rare and challenging disease.